Icu Medical Inc/de (ICUI) · Aug 6, 2026 · Company update

Infusion strength drove a clean beat and raised 2026 targets

Infusion strength drove a clean beat and raised 2026 targets

Expectations were for roughly $544 million of revenue and $1.94 of adjusted EPS; ICU Medical delivered $551.7 million and $2.37. That is a clear quarterly beat versus the published consensus, with revenue about 1% above expectations and adjusted EPS roughly 22% higher.

MetricQ2 2026Q2 2025Market referenceRead
Revenue$551.7M$548.9M~$544.1M consensusBeat (Financial Statements; published consensus)
Adjusted diluted EPS$2.37$2.10~$1.94 consensusBeat (Non-GAAP reconciliation; published consensus)
Adjusted EBITDA$110.0M$100.3M—Up 10% (Adjusted EBITDA reconciliation)
GAAP gross margin43%38%—Up 500 bps (Financial Highlights)
Free cash flow$61.7M$(8.5)M—Sharp improvement (Free Cash Flow reconciliation)
Full-year adjusted EBITDA guidance$415M–$435M$400M–$430M prior—Raised (Fiscal Year 2026 Guidance)
Full-year adjusted EPS guidance$8.60–$9.00$7.75–$8.45 prior—Raised (Fiscal Year 2026 Guidance)

The underlying growth was concentrated in the stronger businesses, especially Infusion Systems. Infusion Systems revenue rose 13% reported and 12% organically, while Consumables grew 5% organically; together they offset a 4% organic decline in Vital Care after adjusting for the prior IV Solutions divestiture. That mix is better than the headline 1% GAAP revenue growth suggests (Segment Revenue and Organic Revenue Reconciliation).

Profitability improved materially, but the quarter’s adjusted result includes meaningful exclusions. Gross margin expanded to 43% from 38%, and adjusted EBITDA rose 10%; however, adjusted EPS benefited from excluding $18.9 million of tariff refunds and other sizable adjustments, including $21.3 million of restructuring and $5.9 million of quality-related remediation. GAAP EPS was only $0.76, down from $1.43, though the prior-year figure included a $41.8 million business-sale gain (Income Statement; Non-GAAP Reconciliation).

The guidance increase is meaningful, but much of the GAAP upgrade is tax-driven rather than a sudden operating reset. The midpoint of adjusted EBITDA guidance increased from $415 million to $425 million, while adjusted EPS guidance midpoint rose from $8.10 to $8.80. GAAP net-income guidance more than doubled at the midpoint, from $35 million to $78 million, reflecting a substantially improved tax outlook and other below-operating-line items in addition to better earnings execution (Fiscal Year 2026 Guidance).

Cash generation and deleveraging add credibility to the positive read. Six-month operating cash flow reached $119.1 million versus $62.5 million, free cash flow rose to $89.3 million from $28.3 million, and debt declined by roughly $54.7 million during the period. Net leverage stood at 2.28x, leaving the balance sheet improved but still meaningfully leveraged (Cash Flow Statement; Net Leverage Ratio Calculation).

Original filing on SEC EDGAR

More Icu Medical Inc/de news

Infusion strength drove a clean beat and raised 2026 targets | ICUI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.